Joseph Vazzano Biography and Net Worth

CFO of Avenue Therapeutics

Mr. Vazzano has served as our Chief Financial Officer (CFO) since February 2019. Prior to CFO, Mr. Vazzano was Avenue’s Vice President of Finance and Corporate Controller (principal financial and accounting officer) since July 2017. Mr. Vazzano joined Avenue from Intercept Pharmaceuticals, Inc., where he served as Assistant Corporate Controller and oversaw the expansion of the company’s finance and accounting department during its transition from development-stage to a fully integrated commercial organization. Prior to Intercept, Mr. Vazzano served as Assistant Controller at Pernix Therapeutics, where he successfully built an accounting and finance team after a corporate restructuring. Earlier in his career, Mr. Vazzano held roles of increasing responsibility in finance and accounting at NPS Pharmaceuticals, a publicly traded biotechnology company acquired by Shire Pharmaceuticals, and was a senior auditor at KPMG, LLP. Mr. Vazzano holds a B.S. in accounting from Lehigh University in Bethlehem, PA, and is a certified public accountant in New Jersey.

What is Joseph Walter Vazzano's net worth?: The estimated net worth of Joseph Walter Vazzano is at least $362.90 thousand as of September 29th, 2025. Mr. Vazzano owns 453,631 shares of Avenue Therapeutics stock worth more than $362,905 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Vazzano may own. Learn More about Joseph Walter Vazzano's net worth.
How do I contact Joseph Walter Vazzano?: The corporate mailing address for Mr. Vazzano and other Avenue Therapeutics executives is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. Avenue Therapeutics can also be reached via phone at (781) 652-4500 and via email at [email protected]. Learn More on Joseph Walter Vazzano's contact information.
Has Joseph Walter Vazzano been buying or selling shares of Avenue Therapeutics?: Joseph Walter Vazzano has not been actively trading shares of Avenue Therapeutics during the last ninety days. Most recently, Joseph Walter Vazzano sold 95 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $121.50, for a transaction totalling $11,542.50. Following the completion of the sale, the chief financial officer now directly owns 870 shares of the company's stock, valued at $105,705. Learn More on Joseph Walter Vazzano's trading history.
Who are Avenue Therapeutics' active insiders?: Avenue Therapeutics' insider roster includes Neil Herskowitz (Director), and Joseph Vazzano (CFO). Learn More on Avenue Therapeutics' active insiders.

Joseph Walter Vazzano Insider Trading History at Avenue Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2021	Sell	95	$121.50	$11,542.50	870
8/20/2020	Sell	51	$909.75	$46,397.25
3/9/2020	Buy	20	$599.25	$11,985.00	790
2/25/2020	Buy	16	$673.50	$10,776.00
8/9/2019	Sell	62	$419.25	$25,993.50	787

Joseph Walter Vazzano Buying and Selling Activity at Avenue Therapeutics

Avenue Therapeutics Company Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Today's Range

Now: $0.80

$0.80

50 Day Range

MA: $0.77

$0.70

$0.93

2 Week Range

Now: $0.80

$0.17

$2.23

Volume

2,077 shs

Average Volume

123,423 shs

Market Capitalization

$2.55 million

P/E Ratio

0.04

Dividend Yield

N/A

Beta